[{"orgOrder":0,"company":"KVK.Tech","sponsor":"Sen-Jam Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Ketotifen Fumarate","moa":"||Histamine H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"KVK.Tech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KVK.Tech \/ KVK.Tech","highestDevelopmentStatusID":"10","companyTruncated":"KVK.Tech \/ KVK.Tech"},{"orgOrder":0,"company":"KVK.Tech","sponsor":"Sen-Jam Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ketotifen Fumarate","moa":"||Histamine H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"KVK.Tech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KVK.Tech \/ KVK.Tech","highestDevelopmentStatusID":"8","companyTruncated":"KVK.Tech \/ KVK.Tech"},{"orgOrder":0,"company":"KVK.Tech","sponsor":"Sen-Jam Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Ketotifen Fumarate","moa":"||Histamine H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"KVK.Tech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KVK.Tech \/ KVK.Tech","highestDevelopmentStatusID":"10","companyTruncated":"KVK.Tech \/ KVK.Tech"},{"orgOrder":0,"company":"KVK.Tech","sponsor":"Medix","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Phentermine Hydrochloride","moa":"Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"KVK.Tech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KVK.Tech \/ Medix","highestDevelopmentStatusID":"15","companyTruncated":"KVK.Tech \/ Medix"},{"orgOrder":0,"company":"KVK.Tech","sponsor":"Sen-Jam Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"SJP-100","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"KVK.Tech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"KVK.Tech \/ KVK.Tech","highestDevelopmentStatusID":"4","companyTruncated":"KVK.Tech \/ KVK.Tech"}]

Find Clinical Drug Pipeline Developments & Deals by KVK.Tech

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : KVK-Tech provides formulation and Manufacturing & Controls for Sen-Jam's first injectable anti-inflammatory therapeutic, SJP-100, which reduces inflammatory protein release from the immune system.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 04, 2024

                          Lead Product(s) : SJP-100

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Recipient : Sen-Jam Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Through the partnership, Medix will gain the exclusive rights to manufacture, distribute, and market Lomaira (Phentermine Hydrochloride) in Mexico. It is indicated for the treatment of obesity.

                          Product Name : Lomaira

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 31, 2024

                          Lead Product(s) : Phentermine Hydrochloride

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Approved FDF

                          Sponsor : Medix

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : SJP-002C (ketotifen) world most potent, orally available anti-inflammatory a person could obtain for a mild to moderate coronavirus infection, Sen-Jam's investigational therapeutic for treatment of COVID-19, SJP-002C is now actively enrolling patients fo...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 05, 2022

                          Lead Product(s) : Ketotifen Fumarate,Indomethacin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Recipient : Sen-Jam Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : KVK will have exclusive manufacturing and supply rights for the product SJP-002C (Ketotifen) in the US. Sen-Jam will utilize the finished formulation and CMC report to enter licensing deals with contracting manufacturing companies (CMOs) globally.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 05, 2022

                          Lead Product(s) : Ketotifen Fumarate,Indomethacin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Recipient : Sen-Jam Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Sen-Jam Pharmaceutical has entered a development, manufacturing, distribution, and license agreement with KVK-Tech. This is a monumental milestone for the company and great news for their promising oral COVID-19 treatment, SJP-002C.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 22, 2022

                          Lead Product(s) : Ketotifen Fumarate,Indomethacin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : Sen-Jam Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank